Talazoparib
Class
Targeted therapy
Subclass
PARP inhibitors
Substance name
Talazoparib
Brand names
Talzenna®
Common formulations
Capsule
Dosage and administration
Adults patients
Treatment of breast cancer in postmenopausal females with PIK3CA mutation without HER2 mutation • Advanced or metastatic, HR-positive
Indications for use
Labeled indications
Adults
Pregnancy and breastfeeding
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource